- Home
- Blog Details
A revolutionary asthma treatment, benralizumab, is instilling hope among the millions grappling with severe asthma, presenting a potential solution to diminish the reliance on high-dose steroid treatments that pose significant health risks.
Severe asthma, impacting approximately 5% of asthma patients, manifests as chest tightness, persistent coughing, and heightened anxiety. While high-dose steroids have traditionally been a primary treatment, their usage comes with severe side effects, including diabetes, osteoporosis, and adrenal suppression.
The uniqueness of benralizumab lies in its approach. Functioning as a monoclonal antibody treatment, it specifically targets immune cells called eosinophils, effectively mitigating inflammation without subjecting patients to the adverse effects associated with steroids.
Results from a recent clinical trial involving over 200 participants showcased remarkable outcomes. An astounding 92% of the individuals were able to safely reduce their steroid intake, with over 60% completely eliminating their dependence on these medications.
This breakthrough offers a safer and potentially life-altering alternative for severe asthma sufferers, promising an enhanced quality of life while mitigating the long-term health risks linked to prolonged steroid use.
Professor David Jackson, the head of the Severe Asthma Centre at Guy's and St Thomas' and a Professor of Respiratory Medicine at King's College London, spearheaded the groundbreaking research, which was published in The Lancet.
Expressing the significance of these findings, Professor Jackson stated, "Biological therapies such as benralizumab have revolutionized severe asthma care in many ways, and the results of this study show for the first time that steroid-related harm can be avoided for the majority of patients using this therapy." This optimistic development signals a transformative shift in managing severe asthma, offering individuals a renewed sense of hope and improved overall well-being.
